Tradestie Institutional Equity Comparison Engine

OKUR vs CBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CBIO Overall Edge

CBIO Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crescent Biopharma, Inc. Common Stock (CBIO) driven by superior Momentum & Technical, Options & Structure while OKUR counters with relative strength in Growth & Margin. Fundamentally, OKUR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, OKUR sits in SURGE (100th %ile IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OKUR N/M vs CBIO N/M Fwd P/E
Growth & Margin Winner OKUR
Op Margin 0.0% vs -1228.4% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CBIO
1Y -2.2% vs -0.2% ยท 52W Pos 20% vs 23%
Options & Structure Winner CBIO
SURGE (100th %ile IV) vs BREAKDOWN (98th %ile IV)
OKUR NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
1M Return +4.65%
1Y Return -2.17%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap $539.5M
1M Return -1.07%
1Y Return -0.23%
Forward P/E N/M
Unified AI Score
49.2 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OKUR -2.17% CBIO -0.23% Spread: +1.94 pp (CBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
OKUR TTM Op. Margin: 0.0% CBIO TTM Op. Margin: -1228.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs CBIO. Trailing 12-month operating profitability (OKUR 0.0% vs CBIO -1228.4%) and valuation multiples (OKUR N/M vs CBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OKUR (2) vs CBIO (4)
Institutional Metric OKUR CBIO Criterion Row Winner
Market Capitalization Scale $113.7M $539.5M Larger Scale CBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% -1228.4% Higher Margin OKUR
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -55.2% -160.8% Higher ROE OKUR
52-Week Range Position Momentum 20% ($2โ€“$5) 23% ($9โ€“$27) Stronger Trend CBIO
Beta / 30D Volatility Risk Regime 0.96ฮฒ ยท 100% Vol 1.18ฮฒ ยท 60% Vol Lower Realized Risk CBIO
Unified Institutional Score Composite Signal 36.0 / 100 (SELL) 49.2 / 100 (HOLD) Higher Composite CBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OKUR vs CBIO Buy Guide
OKUR SURGE
8d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live OKUR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
148d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 98th %ile
IV Regime Extreme (>80th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OKUR nor CBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.